Actinogen Medical (FRA:3AC) ROCE % : -181.06% (As of Dec. 2023)

View and export this data going back to 2007. Start your Free Trial

What is Actinogen Medical ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Actinogen Medical's annualized ROCE % for the quarter that ended in Dec. 2023 was -181.06%.

Actinogen Medical ROCE % Historical Data

The historical data trend for Actinogen Medical's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Actinogen Medical ROCE % Chart

Actinogen Medical Annual Data

Trend

Jun14

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Jun24

ROCE %

Get a 7-Day Free Trial

-39.41

-27.38

-49.06

-58.30

-77.92

Actinogen Medical Semi-Annual Data
	Jun14	Dec14	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24
ROCE %	Get a 7-Day Free Trial															-32.56	-76.41	-44.14	-181.06	-18.49

Actinogen Medical ROCE % Calculation

Actinogen Medical's annualized ROCE % for the fiscal year that ended in Jun. 2024 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Jun. 2024 )		(A: Jun. 2023 )		(A: Jun. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Jun. 2024 )		(A: Jun. 2023 )		(A: Jun. 2024 )
	=	-8.032	/	( ( (9.421 - 1.116)	+	(13.147 - 0.837) )	/ 2 )
	=	-8.032	/	( (8.305	+	12.31)	/ 2 )
	=	-8.032	/	10.3075
	=	-77.92 %

Actinogen Medical's ROCE % of for the quarter that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2023 )		(Q: Jun. 2023 )		(Q: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2023 )		(Q: Jun. 2023 )		(Q: Dec. 2023 )
	=	-14.174	/	( ( (9.421 - 1.116)	+	(8.694 - 1.342) )	/ 2 )
	=	-14.174	/	( ( 8.305	+	7.352 )	/ 2 )
	=	-14.174	/	7.8285
	=	-181.06 %

(1) Note: The EBIT data used here is two times the semi-annual (Dec. 2023) EBIT data.

Actinogen Medical (FRA:3AC) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Actinogen Medical ROCE % Related Terms

Thank you for viewing the detailed overview of Actinogen Medical's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Actinogen Medical Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Actinogen Medical Ltd (FRA:3AC) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

ATGGF:USA ACW:Australia

Address

109 Pitt Street, Level 9, Suite 901, Sydney, NSW, AUS, 2000

Website

https://www.actinogen.com.au

Actinogen Medical Ltd is a biotechnology company. The company develops drugs for Alzheimer's disease and the cognitive decline associated with other neurological diseases. It is focused on the clinical development of Xanamem, an oral medication for neurological diseases amenable to its mechanism of lowering cortisol in brain cells. Geographically, the company's income is derived in Australia.

Actinogen Medical Headlines

No Headlines